Foresite Capital Management IV, LLC Buys Biohaven Pharmaceutical Holding Co, bluebird bio Inc, Kiniksa Pharmaceuticals, Sells The Medicines Co, Aerie Pharmaceuticals Inc, Insmed Inc

• New Purchases: BHVN, BLUE, KNSA, QURE,
• Added Positions: MYOK, KURA,
• Reduced Positions: AERI, INSM, VYGR, CYTK,
• Sold Out: MDCO, ABUS, ASND, OPTN, SIBN, ALEC, CBAY,

For the details of Foresite Capital Management IV, LLC's stock buys and sells, go to https://www.gurufocus.com/guru/foresite+capital+management+iv%2C+llc/current-portfolio/portfolio

1. Cytokinetics Inc (CYTK) - 2,177,292 shares, 37.09% of the total portfolio. Shares reduced by 9.24%
2. MyoKardia Inc (MYOK) - 307,400 shares, 20.82% of the total portfolio. Shares added by 18.06%
3. Insmed Inc (INSM) - 678,322 shares, 15.71% of the total portfolio. Shares reduced by 52.55%
4. Biohaven Pharmaceutical Holding Co Ltd (BHVN) - 156,355 shares, 7.69% of the total portfolio. New Position
5. Voyager Therapeutics Inc (VYGR) - 516,751 shares, 6.83% of the total portfolio. Shares reduced by 37.78%

Foresite Capital Management IV, LLC initiated holding in Biohaven Pharmaceutical Holding Co Ltd. The purchase prices were between $27.51 and $57.29, with an estimated average price of $46.01. The stock is now traded at around $58.80. The impact to a portfolio due to this purchase was 7.69%. The holding were 156,355 shares as of .

Foresite Capital Management IV, LLC initiated holding in bluebird bio Inc. The purchase prices were between $40.39 and $98.04, with an estimated average price of $75.99. The stock is now traded at around $61.27. The impact to a portfolio due to this purchase was 3.32%. The holding were 50,000 shares as of .

Foresite Capital Management IV, LLC initiated holding in Kiniksa Pharmaceuticals Ltd. The purchase prices were between $11 and $19.76, with an estimated average price of $15.6. The stock is now traded at around $20.96. The impact to a portfolio due to this purchase was 1.45%. The holding were 65,000 shares as of .

Foresite Capital Management IV, LLC initiated holding in uniQure NV. The purchase prices were between $40.01 and $73.97, with an estimated average price of $57.92. The stock is now traded at around $63.80. The impact to a portfolio due to this purchase was 1.31%. The holding were 19,082 shares as of .

Foresite Capital Management IV, LLC added to a holding in Kura Oncology Inc by 36.76%. The purchase prices were between $6.45 and $14.04, with an estimated average price of $11.51. The stock is now traded at around $16.65. The impact to a portfolio due to this purchase was 0.36%. The holding were 93,000 shares as of .

Foresite Capital Management IV, LLC sold out a holding in The Medicines Co. The sale prices were between $84.9 and $84.96, with an estimated average price of $84.93.

Foresite Capital Management IV, LLC sold out a holding in Arbutus Biopharma Corp. The sale prices were between $1.01 and $3.42, with an estimated average price of $2.72.

Foresite Capital Management IV, LLC sold out a holding in Ascendis Pharma A/S. The sale prices were between $97.01 and $145.11, with an estimated average price of $130.39.

Foresite Capital Management IV, LLC sold out a holding in OptiNose Inc. The sale prices were between $3.49 and $9.22, with an estimated average price of $6.78.

Foresite Capital Management IV, LLC sold out a holding in SI-BONE Inc. The sale prices were between $8.36 and $22.67, with an estimated average price of $18.5.

Foresite Capital Management IV, LLC sold out a holding in Alector Inc. The sale prices were between $16.25 and $35.28, with an estimated average price of $25.37.